

Menlo Therapeutics COVID-19 Mitigation Efforts

As the COVID-19 pandemic evolves, Menlo is committed to the health, safety and welfare of our employees, patients, customers and their families. We have taken the following steps to help mitigate the spread of the coronavirus:

- Requested all employees in our corporate offices to work from home until further notice
- Notified all employees to follow guidance from their state and local authorities regarding shelter in place orders
- Suspended all domestic and internal business travel
- Suspended in-person sales activity and supplemented sales activity with virtual/digital communications to support information needs and ensure continued communication with health care professionals

During this challenging time, we remain focused on ensuring patients and customers can receive AMZEEQ (minocycline) topical foam, 4%. There is no material disruption to the supply of AMZEEQ, which can be prescribed by physicians and provided by pharmacies nationwide. The following systems are in place to meet any information needs:

- Patients may visit [AMZEEQ.com](https://www.amzeeq.com) for patient-friendly product information, co-pay assistance or for [patient prescribing information](#).
- Healthcare providers may visit [AmzeeqHCP.com](https://www.amzeeqhcp.com) for product information, support materials and [prescribing information](#), or may contact their sales representatives
- Side effects or product quality concerns can be reported by email to pvinfos@foamix.com, or by phone at [1-844-375-3673](tel:1-844-375-3673)
- Medical information can be obtained by emailing medinfo@foamix.com, or by calling [1-844-375-3673](tel:1-844-375-3673)

We will continue to monitor this developing situation; heed direction provided by the Centers for Disease Control and Prevention and other federal, state, and local public health and administration officials; and adjust approaches as information evolves.

At Menlo, protecting and supporting the safety of our employees, patients, healthcare provider customers, and their families is the utmost priority. We hope that our actions, combined with those of national, state and local authorities will mitigate the spread of the virus soon and we are back to normal business operations in the coming weeks.

Foamix Pharmaceuticals is a wholly owned subsidiary of Menlo Therapeutics.